Shionogi & Co Ltd (SGIOF) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

My name is Kyokawa from Shionogi PR Department. Thank you very much for joining us today. This is Shionogi, the financial briefing of the result of the first quarter of 2024. Let me introduce who we have today. First, Dr. John Keller, Senior Executive Officer, Senior Vice President. Senior Vice President, Healthcare Business Supervisory Unit, Dr. Iwasaki. Senior Executive Officer, Senior Vice President, Supply Unit, Dr. Hanazaki. Senior Executive Officer, Senior Vice President, Corporate Business Strategy Division, Dr. Hata Naka. Corporate Officer, Senior Vice President, Dr. Uehara. And then, Vice President, Finance and Accounting, Dr. Kudo. Now let me briefly explain the format for today. We'll introduce the result of the first quarter and also the progress of the pipeline, followed by a Q&A. We are planning to complete the session at 5 o'clock. As to the financial results, Dr. Kudo and Dr. Hatanaka will have a briefing, and then Dr. Wihara and Dr. John Keller will talk about the progress of the pipeline. Today, we have the vice presidents from four divisions and also the head of the R&D and head of finance. We are ready to answer any questions. And now, let me explain simultaneous translation. Simultaneous translation is available today. If you wish to use simultaneous translation, please choose either Japanese or English by clicking the globe icon. Now, let us start. Dr. Kudo. I'll explain the overview of the first quarter financial results. Please refer to page 4 for the highlights. At the left side, revenue was ¥97.6 billion, down from ¥109.3 billion in the previous year. The main reason for this decline was the ¥25 billion one-time payment from the transfer of the ADHD drug license in the first quarter of the previous year. Excluding this, revenue increased by ...